Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
30 oktober, 13:00
30 oktober, 13:00
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
PR Newswire
GAITHERSBURG, Md., Oct. 30, 2025
GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025 . Details of the event and replay are as follows:
Conference call details: | |
Date: | November 6, 2025 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 (U.S.) or |
(+1) (646) 357-8766 (International) | |
Webcast: |
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, November 6, 2025, until |
Dial-in number: | (800) 770-2030 (U.S.) or |
(+1) (609) 800-9909 (International) | |
Passcode: | 3585070# |
Webcast: | ir.novavax.com/events , until December 5, 2025 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M ® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay , CFA
240-268-2022
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com

SOURCE Novavax, Inc.

30 oktober, 13:00
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
PR Newswire
GAITHERSBURG, Md., Oct. 30, 2025
GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025 . Details of the event and replay are as follows:
Conference call details: | |
Date: | November 6, 2025 |
Time: | 8:30 a.m. ET |
URL to register phone: | |
Dial-in number: | (888) 880-3330 (U.S.) or |
(+1) (646) 357-8766 (International) | |
Webcast: |
Replay details: | |
Date: | Available starting at 11:30 a.m. ET, November 6, 2025, until |
Dial-in number: | (800) 770-2030 (U.S.) or |
(+1) (609) 800-9909 (International) | |
Passcode: | 3585070# |
Webcast: | ir.novavax.com/events , until December 5, 2025 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M ® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay , CFA
240-268-2022
ir@novavax.com
Media
Yvonne Sprow
844-264-8571
media@novavax.com

SOURCE Novavax, Inc.

Bank
Analyser
Aktieråd
Rapporter


Bank
Analyser
Aktieråd
Rapporter


OMX Stockholm 30
1 DAG %
Senast
2 767,07
